To economists looking at drug prices under Medicare Part D, the focus on giving the federal government price negotiation authority is misguided. To exert power over prices, a negotiator has to be able to move market share. And ultimately, that means they have to have the power to exclude coverage.
Since the House proposal to authorize price negotiation under Medicare Part D (HR 4) explicitly prohibits creation of a national...






